ALSO NOTED: Pfizer focuses on expanding inhaled meds R&D; Bayer's Avelox linked to liver problems;

> Pfizer is budgeting €130 million for the construction of a new facility in France to specialize in the development of inhaled meds. Report

> Bayer warned doctors that its Avelox antibiotic may lead to potentially fatal liver damage and skin disease in rare cases. Report

> Orchid Chemicals and Pharmaceuticals got FDA approval for its non-antibiotic anti-emetic drug granisetron hydrochloride. Report

> MiddleBrook Pharma has hired the investment bankers at Morgan Stanley to explore strategic alternatives, including a possible sale of company assets. Report

> A new study shows that drug-coated balloons were better at keeping leg arteries open than were conventional balloon catheters. Report

> Websites that states use to help consumers compare prescription prices often have missing, outdated, or inaccurate information, according to a report from the Center for Studying Health System Change. Report

> Vertex Pharmaceuticals plans to sell senior convertible notes and 6 million shares of common stock to raise $405 million. Report

> A new investigation by USA Today suggests that corporate policies for retail pharmacies such as Walgreens and CVS--which together fill almost one-third of all U.S. prescriptions--could promote errors by encouraging pharmacists to work at the highest possible speed. Report

> Despite spending a dramatically higher amount than before on treatments for spinal pain, Americans aren't getting great results, according to a new study. Report

> With its stock in a swoon, Nastech has cut 50 more positions. Report

And Finally... Athletes may get protection from coughs and colds by using probiotic supplements. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.